Skip to main content
Jinyu Bio-Technology Co.,Ltd. logo

Jinyu Bio-Technology Co.,Ltd. — Investor Relations & Filings

Ticker · 600201 ISIN · CNE000000Y37 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,777 across all filing types
Latest filing 2018-07-03 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600201

About Jinyu Bio-Technology Co.,Ltd.

http://jinyubiotech.com/

Jinyu Bio-Technology Co., Ltd. focuses on the research, development, and manufacturing of veterinary biological products and pharmaceuticals. The company is a prominent supplier of animal vaccines, particularly specializing in Foot-and-Mouth Disease (FMD) vaccines, brucellosis vaccines, and solutions for swine and poultry diseases. It utilizes advanced biotechnology platforms, including large-scale suspension culture and high-efficiency purification processes, to produce high-titer, high-purity biologicals. The organization operates sophisticated research facilities and Biosafety Level 3 (P3) laboratories to support the development of diagnostic reagents and preventive treatments. Its operations center on enhancing animal health through scientific innovation, providing comprehensive disease control strategies for the global livestock industry and large-scale agricultural operations.

Recent filings

Filing Released Lang Actions
独立董事关于公司2017年度限制性股票股权激励计划首次授予限制性股票第一期解锁的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent director's opinion on the unlocking of restricted stock under a 2017 equity incentive plan. It references compliance with stock incentive management regulations and company bylaws, and provides an independent opinion on the legality and appropriateness of the stock unlocking. The document is short (997 characters) and consists mainly of an independent opinion rather than detailed financial data or a full report. It is not an annual report, audit report, or earnings release. It is also not a proxy solicitation or voting result announcement. The content fits best under a regulatory or compliance filing related to management or governance but does not detail governance structure itself. Given the nature and length, it is best classified as a Regulatory Filing (RNS), which is the fallback for miscellaneous filings that do not fit other categories.
2018-07-03 Chinese
经世律师事务所关于金宇生物技术股份有限公司2017年度限制性股票股权激励计划首次授予的限制性股票第一期解锁事项之法律意见书
Regulatory Filings
2018-07-03 Chinese
第九届董事会第十四次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of resolutions passed at a board meeting of 金宇生物技术股份有限公司 (Jinyu Biotechnology Co., Ltd.). It details the approval of performance assessment opinions and the unlocking of restricted stock under a 2017 stock incentive plan. The document includes voting results and mentions the board of directors and related procedures. It does not contain financial statements or detailed financial data, nor is it a full report or presentation. It is clearly a board/management information announcement regarding decisions made by the board, specifically about stock incentive plans and related corporate governance matters. Therefore, the appropriate classification is Board/Management Information (MANG). The document length is short (1062 characters), and it is not a report publication announcement or regulatory filing. Confidence is high due to clear content and context.
2018-07-03 Chinese
关于使用闲置自有资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by 金宇生物技术股份有限公司 regarding the progress of using idle self-owned funds for cash management. It details investment amounts, types, expected returns, counterparties, and risk control measures. The document is relatively short (3163 characters) and focuses on updates about financing activities related to cash management investments. It does not contain financial statements, audit opinions, or detailed financial results. It is not an annual or interim report, nor a call transcript or management report. The content fits best with a Capital/Financing Update (CAP) as it provides updates on the company's use of funds and investment activities.
2018-06-29 Chinese
关于第一大股东进行股票质押式回购交易的公告
Transaction in Own Shares Classification · 95% confidence The document is an announcement regarding the pledge of shares by the company's largest shareholder. It details the number of shares pledged, the purpose of the pledge, and the shareholder's financial status. There is no financial report, earnings data, or management discussion. The content fits the description of a Transaction in Own Shares (POS) as it involves share pledge and repurchase transactions by a major shareholder. The document length is short and focused solely on this transaction, confirming it is not a full financial report or other category.
2018-06-29 Chinese
关于董事、监事及高级管理人员增持公司股份计划的公告
Director's Dealing Classification · 95% confidence The document is an announcement regarding a plan by company directors, supervisors, and senior management to increase their holdings in the company's shares. It details the participants, the amount and method of share purchases, the purpose of the plan, and compliance with regulatory requirements. There are no financial statements, earnings data, or detailed financial analysis present. The document is a formal disclosure of insider share purchase plans by management, which fits the category of Director's Dealing (DIRS). The document length is 1872 characters, which is typical for such announcements and not a full report or regulatory filing. Therefore, the classification is DIRS with high confidence.
2018-06-20 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.